ERAS 4001
Alternative Names: ERAS-4001Latest Information Update: 11 Aug 2025
At a glance
- Originator Medshine Discovery
- Developer Erasca
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 06 Aug 2025 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Combination therapy) in USA (PO) (NCT07021898)
- 06 Aug 2025 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy) in USA (PO) (NCT07021898)
- 23 Jun 2025 Erasca plans the first-in-human phase I/Ib BOREALIS-1 trial for Solid tumours (Metastatic disease, Late-stage disease, Combination therapy, Monotherapy) (PO), in August 2025 (NCT07021898)